Is GENELUX Corp (GNLX) Halal?

NASDAQ Healthcare United States $111M
✗ NOT HALAL
Confidence: 83/100
GENELUX Corp (GNLX) is Not Halal under AAOIFI Standard 21. The company's impermissible income ratio of 18212.5% exceeds the 5% threshold allowed under AAOIFI. GENELUX Corp operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 1.5%
/ 30%
25.5%
/ 30%
0.0%
/ 30%
18212.5%
/ 5%
✗ NOT HALAL
DJIM 1.5%
/ 33%
25.5%
/ 33%
0.0%
/ 33%
18212.5%
/ 5%
✗ NOT HALAL
MSCI 5.4%
/ 33%
89.0%
/ 33%
0.0%
/ 33%
18212.5%
/ 5%
✗ NOT HALAL
S&P 1.5%
/ 33%
25.5%
/ 33%
0.0%
/ 33%
18212.5%
/ 5%
✗ NOT HALAL
FTSE 5.4%
/ 33%
89.0%
/ 33%
0.0%
/ 50%
18212.5%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-0.86
P/B Ratio
8.1
EV/EBITDA
-2.9
EV: $97M
Revenue
$8,000
Beta
0.1
Low volatility
Current Ratio
2.4

Profitability

Gross Margin 100.0%
Operating Margin -117650.0%
Net Margin 0.0%
Return on Equity (ROE) -170.0%
Return on Assets (ROA) -77.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$21M
Free Cash Flow-$22M
Total Debt$2M
Debt-to-Equity14.6
Current Ratio2.4
Total Assets$35M

Price & Trading

Last Close$2.63
50-Day MA$2.66
200-Day MA$3.86
Avg Volume240K
Beta0.1
52-Week Range
$1.99
$8.54

About GENELUX Corp (GNLX)

CEO
Mr. Thomas D. Zindrick J.D.
Employees
25
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$111M
Currency
USD

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is GENELUX Corp (GNLX) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), GENELUX Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is GENELUX Corp's debt ratio?

GENELUX Corp's debt ratio is 1.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.4%.

What are GENELUX Corp's key financial metrics?

GENELUX Corp has a market capitalization of $111M, and revenue of $8,000. Return on equity stands at -170.0%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.